ArticleBlood science (Baltimore, Md.)2025
Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis.
Xiaodan Luo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.